Research platform
Research platform of Noxi Lab allows generating original hybrid molecules from endogenous bioregulators, pharmacologically active compounds and nitric oxide donors (NO-donors)
Main News
* Gurus successfully completed preclinical trials of asthma treatment drug * Magazine Kommersant published an article about promising multifunctional drug candidates of Gurus BioPharm * Gurus raises $0.7M for preclinical trials of a drug for asthma

Investments in biomedical innovations

Gurus BioPharm LLC (“Gurus”) is a research and investment company developing innovative drugs. We finance and develop groundbreaking Russian biopharmaceutical innovations from the early stages to commercialization at the global market. We provide an opportunity for accredited private investors to co-invest with us in cutting-edge innovations that can change current standards of healthcare in the world.

Projects for investment:

Innovative drugs

Innovative drugs
Respiratory system
GUR-501 Asthma treatment First in class

GUR-501 has a potential to be first drug with new mode of action. Asthma causes acute bronchospasm. ~5% of population suffer from asthma. Funded: $721,000. Supported by

Stage: Preclinical trials
Innovative drugs
Genito-urinary system
GUR-001 Erectile dysfunction treatment (ED)

Unique drug candidate that is expected to have a sufficient advantage vs MUSE suppository: higher efficiency and no pain effect. Unlike Caverject, injections are not needed. 25% of men aged 40-70  have moderate ED, and 10% of men have severe ED

Stage: Discovery research
Innovative drugs
Cardiovascular system
GUR-201 Critical Limb Ischemia treatment (CLI) Best-in-class

GUR-201 is designed to treat CLI caused by diabetes or peripheral artery disease. CLI leads to severe complications up to amputation. 1%-2% of population suffer CLI

Stage: Preclinical trials
All projects...

Highly Effective cosmetics

Highly Effective cosmetics
Hair growth stimulation
REG-101 Eyelash growth stimulator Fast Launch

An innovative molecular complex, that more effectively stimulates growth of eyelashes. Competitors are Latisse, Careprost and more than 10 brands on the basis of generic pharmaceutical substance called bimatoprost. ~ 6% of women use  means for eyelash growth

Stage: Product registration
Highly Effective cosmetics
Anti-aging line
REG-201 Anti-aging skin recovery Fast Launch

This innovative complex allows to restore moisture and elasticity of the skin by restoring the power of the capillary network, which decreases with age

Stage: Safety study
Highly Effective cosmetics
Hair growth stimulation
REG-103 Hair growth stimulator Fast Launch

This innovative molecular complex acts on hair follicles stimulating hair growth on a head by increasing blood supply to follicles

Stage: Product registration
All projects...

Synergy of investment and research capabilities

Unlike traditional life sciences funds, Gurus conducts scientific research of original molecules. Therefore, we can enter the projects before the traditional venture funds, at the stage of scientific research. Projects with some incompleteness in technology development do not confuse us, if they have strong innovative potential. Gurus has expertise and technological capabilities to eliminate the shortcomings of the project and to unlock its potential.

Our technologies in drug development

Gurus has strong research competencies and platform technologies in drug development. Noxi Lab is a technological unit of Gurus which develops a research platform for generating innovative drugs, based on nitric oxide donors and pharmaceutical substance hybridization technology which uses biologically active linkers.

Joint investments in drug development

Gurus offers to accredited private investors to co-invest together with us in biopharmaceutical innovations. Traditional life sciences venture funds and pharmaceutical companies do not collaborate with private investors. Investing in innovative drugs is assumed to be one of the most profitable and fastest growing industries in the world and can be an interesting alternative to investing in shares of mature public companies.

Our startups
Our project companies are Prostanit development, LLC, Noxi Lab, LLC